Clinical Trial Update: Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial update on the immunogenicity and safety of Infanrix-IPV+Hib vaccine from GlaxoSmithKline, completed with posted results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix IPV/Hib (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b vaccine (DTaP-IPV-Hib))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2013-04-02